NOMOS Glashütte/SA Roland Schwertner KG
6
In record time! NOMOS Ahoi: An extreme swimmer
more
Stories from Basel
- Language:
- Media:
- Period:
- Period:Total
Swiss Rockets AG announces the founding of ROCKETVAX for the development of a next-generation SARS-CoV-2 vaccine
moreVersameb raises CHF 6 million and strengthens team to advance its VERSagile technology platform towards clinical trials
Basel, Switzerland (ots) - Versameb AG, a biopharmaceutical company developing innovative ribonucleic acid (RNA) therapeutics, announced today the closing of a CHF 6 million seed financing round. Versameb further strengthens its team by the appointment of Dr. Klaas P. Zuideveld as Chief Development Officer effective ...
moreEANS-Adhoc: ams AG / Repurchase of own shares on the ordinary trading line
issuer: ams AG Tobelbader Strasse 30 A-8141 Premstaetten phone: +43 3136 500-0 FAX: +43 3136 500-931211 mail: investor@ams.com WWW: www.ams.com ISIN: AT0000A18XM4 indexes: stockmarkets: SIX Swiss Exchange language: ...
moreINTERNATIONAL SERVICE CHECK becomes ISC-CX
Munich/Basel (ots) - After more than 20 years, Europe's leading Mystery Shopping provider INTERNATIONAL SERVICE CHECK is rebranding to ISC-CX to reflect the company's evolution to a full-service, digital customer experience agency. The company has been repositioned to leverage its unique capabilities and architecture to serve different customer experience needs, beyond mystery shopping. ISC-CX has extended its portfolio ...
moreJenny Fleischer named Vice President Marketing Excellence of Ottobock
moreKat Florence acquires rare antique 55.66-carat Colombian Emerald found in Italy by the extreme Gem Hunter Don Kogen
moreVersameb raises CHF 6.4 million in Seed C round and strengthens the team
Basel (ots) - Versameb AG, a Swiss biopharmaceutical company, announced today the successful closing of a CHF 6.4 million Seed C financing round, bringing the total capital raised to date to CHF 11.8 million. Versameb is focusing on the discovery and development of innovative, next-generation RNA-based drugs. The proceeds of this financing round will be used to expand ...
moreMundipharma EDO GmbH: US FDA Grants Orphan Drug Designation for Tinostamustine in Very Rare Blood Cancer
Basel, Switzerland (ots/PRNewswire) - FOR EX-US MEDICAL AND TRADE MEDIA ONLY - T-cell prolymphocytic leukaemia is an extremely rare and aggressive T-cell leukaemia, with very limited effective treatment options1,2 - Tinostamustine is in very early phase clinical trials to investigate it as a potential future ...
more
1